Caricamento...
Bacillus Calmette–Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccine
Since the first report in 1976, accumulated clinical evidence has supported intravesical Bacillus Calmette–Guerin (BCG) therapy as one of the standard methods of management of intermediate‐ and high‐risk non‐muscle invasive bladder cancer. Despite its efficacy, intravesical BCG therapy is associated...
Salvato in:
| Pubblicato in: | Cancer Sci |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7657210/ https://ncbi.nlm.nih.gov/pubmed/23181987 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12075 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|